Custom Semax CAS: 80714-61-0 - Premium Synthetic Peptide from China Suppliers and Factory for CNS Enhancement Manufacturers, Pricelist
Semax is a synthetic peptide drug that originated from a segment of the adrenocorticotropic hormone (ACTH). Developed in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax is unique among peptides as it eliminates hormonal activity while preserving and amplifying its powerful effects on the central nervous system. As a leading product from notable suppliers in China, Semax is manufactured in state-of-the-art factories ensuring high quality and efficacy. This innovative peptide offers significant cognitive and neuroprotective benefits, making it a popular choice for those seeking to enhance mental performance and overall brain health.
Semax is a synthetic peptide drug derived from a fragment of adrenocorticotropic hormone (ACTH). It was initially developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike its parent hormone ACTH, which primarily affects the adrenal glands, Semax removes hormonal activity but retains and significantly enhances its potent effects on the central nervous system.
Therapeutic Areas
Semax shows great therapeutic potential primarily in the fields of neuroscience and psychiatry.
Stroke (Ischemic)
This is the main indication for which Semax has been approved in Russia. It is used in the acute and recovery phases to limit the infarct area, protect dying neurons, and promote functional recovery.
Cognitive Impairment
Used to treat vascular and post-traumatic cognitive impairment, it can improve memory, attention and psychological performance.
Anxiety & Depressive Disorders
As an adjunct therapy, especially effective for depressive states associated with burnout and cognitive decline.
Neurodegenerative Diseases
Its potential for use in Alzheimer's and Parkinson's diseases is being investigated, primarily based on its neurotrophic and protective effects.
Optic Neuropathy
Used to treat optic nerve damage and atrophy caused by diseases such as glaucoma.
Cognitive Enhancement
In some regions (for non-medical purposes), it is used as a "nootropic" to enhance learning, memory, and mental concentration under stress.
Outlook & Development
Semax has a promising future, but it also faces some challenges:
Prospects and Opportunities
Expanding indications: The greatest potential lies in its application to a wider range of neurodegenerative diseases. Preclinical and clinical studies are underway for Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Combination therapy: Semax may be used in combination with other neuroprotective agents or rehabilitation therapies to produce a synergistic effect and enhance treatment outcomes.
Development of novel analogues: Researchers are developing analogues that are more potent and have a longer duration of action than Semax (e.g., Selank is used for anxiety, and Adamamax is a more stable version of Semax).
Global market expansion: Currently, Semax is mainly used in Russia and some Eastern European countries. If it can pass rigorous clinical trials and obtain regulatory approval (such as FDA approval) in developed Western countries (such as the United States and the European Union), it will greatly promote its global application.
Challenges and Future Development
Rigorous clinical validation: Although there has been extensive research in the former Soviet Union, its efficacy and safety still need to be confirmed through large-scale clinical trials that meet international standards (such as randomized, double-blind, placebo-controlled trials) to meet the requirements of regulatory agencies such as the FDA and EMA.
Precise elucidation of the mechanism of action: Although there is a basic understanding of its mechanism, more precise molecular pathways still need to be explored.
Commercialization and awareness: Globally, Semax has far lower awareness than traditional neurological drugs, requiring extensive market education and commercial promotion.
Frequently Asked Questions
What is Semax and where was it originally developed?
Semax is a synthetic peptide drug derived from a fragment of adrenocorticotropic hormone (ACTH). It was developed in the 1980s in Russia by the Institute of Molecular Genetics of the Russian Academy of Sciences.
How does Semax differ from the ACTH hormone?
Unlike the natural ACTH hormone which primarily affects adrenal gland function, Semax completely removes hormonal activity while retaining and significantly boosting targeted central nervous system effects.
What is the primary approved medical use for Semax?
Ischemic stroke is the main indication for which Semax is approved in Russia. It is administered during acute and recovery phases to limit infarct size, protect dying neurons, and assist functional neurological recovery.
Can Semax be used for cognitive enhancement in healthy individuals?
Yes, in certain regions it is utilized off-label or non-medically as a nootropic compound to enhance learning capacity, memory retention, and mental concentration under high-stress conditions.
What are the main barriers to Western approval (FDA/EMA) for Semax?
To receive approval from Western regulatory agencies like the FDA or EMA, Semax requires large-scale, international-standard clinical validation (such as randomized double-blind placebo-controlled trials) alongside deeper molecular mechanism mapping.
What next-generation analogues are derived from Semax research?
Researchers are developing more potent and stable analogues, including Selank (commonly targeted for anxiety disorders) and Adamamax (engineered as a longer-lasting, more stable version of Semax).
Thin
